166 related articles for article (PubMed ID: 31779047)
1. Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low-dose afatinib: A case report.
Iida Y; Kumasawa F; Shimizu T; Shintani Y; Takahashi N; Gon Y
Thorac Cancer; 2020 Feb; 11(2):447-450. PubMed ID: 31779047
[TBL] [Abstract][Full Text] [Related]
2. Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.
Long Y; Zhang K; Li Y; Yu M; Zhu J; Huang M
Ann Palliat Med; 2020 Sep; 9(5):3609-3613. PubMed ID: 32648452
[TBL] [Abstract][Full Text] [Related]
3. Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
Tamura T; Kawakado K; Makimoto G; Nakanishi M; Kuyama S
Thorac Cancer; 2021 Jun; 12(11):1770-1774. PubMed ID: 33942527
[TBL] [Abstract][Full Text] [Related]
4. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam.
Vu TH; Nguyen HTT; Dao LK; Duong CK; Nguyen CV; Doan TT; Nguyen HTT; Hoang HH; Dinh DK; Le GV; Vu TT; Truong MC; Nguyen LT
Asian Pac J Cancer Prev; 2021 May; 22(5):1581-1590. PubMed ID: 34048189
[TBL] [Abstract][Full Text] [Related]
6. Long-term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Shijubou N; Sumi T; Kamada K; Sawai T; Yamada Y; Nakata H; Mori Y; Chiba H
Thorac Cancer; 2021 Mar; 12(6):989-992. PubMed ID: 33533191
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib.
Longo V; Catino A; Montrone M; Pizzutilo P; Pesola F; Marech I; Capone I; Prelaj A; Galetta D
Thorac Cancer; 2021 Jul; 12(13):2031-2034. PubMed ID: 34008923
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T;
Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992
[TBL] [Abstract][Full Text] [Related]
9. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
Moran T; Taus A; Arriola E; Aguado C; Dómine M; Rueda AG; Calles A; Cedrés S; Viñolas N; Isla D; Palmero R; Sereno M; Diaz V; Juan O; Marsé R; Martorell PM; Sánchez Torres JM;
Clin Lung Cancer; 2020 Sep; 21(5):428-436.e2. PubMed ID: 32461037
[TBL] [Abstract][Full Text] [Related]
10. Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations.
Masuda T; Sunaga N; Kasahara N; Takehara K; Yatomi M; Hara K; Koga Y; Maeno T; Hisada T
Thorac Cancer; 2020 Aug; 11(8):2351-2356. PubMed ID: 32529804
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.
Pang LL; Gan JD; Tan JR; Huang YH; Liao J; Liang WT; Deng PB; Fang WF
Cancer; 2022 Nov; 128(21):3804-3814. PubMed ID: 36069292
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay.
Kimura S; Tanaka K; Harada T; Liu R; Shibahara D; Kawano Y; Nakanishi Y; Okamoto I
Cancer Sci; 2018 Nov; 109(11):3657-3661. PubMed ID: 30255614
[TBL] [Abstract][Full Text] [Related]
13. Afatinib for the treatment of
Harvey RD; Adams VR; Beardslee T; Medina P
J Oncol Pharm Pract; 2020 Sep; 26(6):1461-1474. PubMed ID: 32567494
[TBL] [Abstract][Full Text] [Related]
14. Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.
Jiang Y; Fang X; Xiang Y; Fang T; Liu J; Lu K
Curr Oncol; 2023 May; 30(6):5337-5349. PubMed ID: 37366888
[TBL] [Abstract][Full Text] [Related]
15. Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.
Kutsuzawa N; Takahashi F; Tomomatsu K; Obayashi S; Takeuchi T; Takihara T; Hayama N; Oguma T; Aoki T; Asano K
Tokai J Exp Clin Med; 2020 Sep; 45(3):113-116. PubMed ID: 32901897
[TBL] [Abstract][Full Text] [Related]
16. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
17. Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.
Han C; Ding X; Li M; Luo N; Qi Y; Wang C
J Cancer Res Clin Oncol; 2022 May; 148(5):1265-1268. PubMed ID: 35230510
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib.
Ikeuchi T; Tokuyasu H; Ishikawa S
Intern Med; 2019; 58(1):101-104. PubMed ID: 30606938
[TBL] [Abstract][Full Text] [Related]
19. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
[TBL] [Abstract][Full Text] [Related]
20. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]